Findings

What do systematic reviews say?

204 questions · 205 findings · 17 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 69 · 33.7%GRADE not reported 9 · 4.4%Very low 29 · 14.1%Low 36 · 17.6%Moderate 50 · 24.4%High 12 · 5.9%

14 days inhaled AZLI plus 14 days placebo vs 28 days inhaled AZLI

Growth and nutritional status · children and adolescents with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

14 days inhaled AZLI plus 14 days placebo vs 28 days inhaled AZLI

Frequency of infective pulmonary exacerbations: number of exacerbations per patient year · children and adolescents with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

14 days inhaled AZLI plus 14 days placebo vs 28 days inhaled AZLI

Isolation of other micro‐organisms from the respiratory tract: number of positive cultures per patient year · children and adolescents with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

14 days inhaled AZLI plus 14 days placebo vs 28 days inhaled AZLI

Adverse effects of antibiotics: number of participants reporting a serious adverse event · children and adolescents with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Laser therapy vs no laser therapy

Regression of PSR: change in number and size (in clock hours or in degrees of retinal circumference) of new blood vessels · children and adults with SCD and PSR

1 finding from 1 review

Laser therapy for retinopathy in sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 247 participants
Very low

Laser therapy vs no laser therapy

Development of new PSR: proliferation of blood vessels at a new area/progression of existing PSR after treatment · children and adults with SCD and PSR

1 finding from 1 review

Laser therapy for retinopathy in sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 247 participants
Very low

Laser therapy vs no laser therapy

Quality of life · children and adults with SCD and PSR

The review found no eligible studies for this question.

1 finding from 1 review

Laser therapy for retinopathy in sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Laser therapy vs no laser therapy

Change in visual loss associated with PSR: visual loss is defined by the deterioration of visual acuity of 3 lines or more with the Snellen chart · children and adults with SCD and PSR

1 finding from 1 review

Laser therapy for retinopathy in sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 414 participants
Very low

Laser therapy vs no laser therapy

Occurence of vitreous haemorrhage · children and adults with SCD and PSR

1 finding from 1 review

Laser therapy for retinopathy in sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 414 participants
Low

Laser therapy vs no laser therapy

Adverse effects · children and adults with SCD and PSR

1 finding from 1 review

Laser therapy for retinopathy in sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 414 participants
Low

Intervention not reported

Lung function Mean percentage change in FEV1 · adults and children with cystic fibrosis

1 finding from 1 review

Once‐daily versus multiple‐daily dosing with intravenous aminoglycosides for cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 289 participants
Moderate

Intervention not reported

Lung function Mean percentage change in FVC (% predicted) · adults and children with cystic fibrosis

1 finding from 1 review

Once‐daily versus multiple‐daily dosing with intravenous aminoglycosides for cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 70 participants
Low

Intervention not reported

Nutritional status BMI · adults and children with cystic fibrosis

1 finding from 1 review

Once‐daily versus multiple‐daily dosing with intravenous aminoglycosides for cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Low

Intervention not reported

Time to first exacerbation requiring intravenous antibiotics · adults and children with cystic fibrosis

1 finding from 1 review

Once‐daily versus multiple‐daily dosing with intravenous aminoglycosides for cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 113 participants
Moderate

Intervention not reported

Antibiotic resistance patterns following treatment · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Once‐daily versus multiple‐daily dosing with intravenous aminoglycosides for cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Ototoxicity An increase in auditory threshold of 20 dB or more over any frequency range · adults and children with cystic fibrosis

The intervention showed no clear difference in ototoxicity An increase in auditory threshold of 20 dB or more over… (low certainty).

1 finding from 1 review

Once‐daily versus multiple‐daily dosing with intravenous aminoglycosides for cystic fibrosis 2019 · Cochrane Headline outcomes only
RR 0.56 [0.04, 7.96]
3 studies · 266 participants
Low

Intervention not reported

Nephrotoxicity The percentage change in creatinine over baseline · adults and children with cystic fibrosis

1 finding from 1 review

Once‐daily versus multiple‐daily dosing with intravenous aminoglycosides for cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 245 participants
Moderate

Summary of findings: cycled vs culture‐based antibiotic therapy

Time to next isolation of PA · children (aged 1 to 12 years) with CF and a newly isolated PA infection

Summary of findings: cycled probably leads to higher time to next isolation of PA compared with culture‐based antibiotic therapy (moderate certainty).

1 finding from 1 review

Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis 2019 · Cochrane Headline outcomes only
HR 2.04 [1.28, 3.26]
1 study · 253 participants
Moderate

Summary of findings: cycled vs culture‐based antibiotic therapy

Quality of life · children (aged 1 to 12 years) with CF and a newly isolated PA infection

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: cycled vs culture‐based antibiotic therapy

Lung function: FEV1 mL (change from baseline) · children (aged 1 to 12 years) with CF and a newly isolated PA infection

1 finding from 1 review

Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 131 participants
Very low